Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab in extensive small cell lung cancer
NCT06406673Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Aug 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of cadonilimab in small cell lung cancer (SCLC) (2 cohorts), sponsored by Henan Cancer Hospital. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
cadonilimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06406673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06406673.